Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pediatric ulcerative colitis study of upadacitinib with open-label induction, randomized double-blind maintenance, and long-term open-label extension
MOH_2023-12-05_013095Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in autoimmune colitis (6 arms), sponsored by AbbVie Inc. Started Dec 2023; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2023-12-05_013095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-12-05_013095.